

APPENDIX **XI**

*TUMOR ASSOCIATED  
MUTATIONS IN RET*

Domain	Mutation	Tumor Type
Cadherin	p.R163Q	Large intestine carcinoma
	p. R330W	Glioblastoma
	p.G532 L534>EEC	Thyroid medullary carcinoma
	p.G533C	Thyroid medullary carcinoma
	p.F555L	Lung adenocarcinoma
Cysteine rich	p.V591I	Thyroid medullary carcinoma
Cysteine rich	p.G592 G607del	Thyroid medullary carcinoma
Cysteine rich	p.K603G	Thyroid medullary carcinoma
Cysteine rich	p.C609R	MEN2A
Cysteine rich	p.C609S	MEN2A
Cysteine rich	p.C609Y	Adrenal gland pheochromocytoma
Cysteine rich	p.C611G	Thyroid medullary carcinoma
Cysteine rich	p.C611S	MEN2A/thyroid medullary carcinoma
Cysteine rich	p.C611W	MEN2A/thyroid medullary carcinoma
Cysteine rich	p.C611Y	MEN2A/thyroid medullary carcinoma
Cysteine rich	p.F612 C620del	Thyroid medullary carcinoma
Cysteine rich	p.C618F	MEN2A/thyroid medullary carcinoma
Cysteine rich	p.C618G	MEN2A/thyroid medullary carcinoma
Cysteine rich	p.C618R	MEN2A/thyroid medullary carcinoma
Cysteine rich	p.C618S	MEN2A/thyroid medullary carcinoma
Cysteine rich	p.C618Y	Adrenal gland pheochromocytoma
		MEN2A/thyroid medullary carcinoma
Cysteine rich	p.C618*	MEN2A

## 2 TARGETING PROTEIN KINASES FOR CANCER THERAPY

Cysteine rich	p.C620G	MEN2A
Cysteine rich	p.C620F	MEN2A/thyroid medullary carcinoma
Cysteine rich	p.C620R	MEN2A/thyroid medullary carcinoma
Cysteine rich	p.C620S	MEN2A/thyroid medullary carcinoma
Cysteine rich	p.C620Y	MEN2A/thyroid medullary carcinoma
Cysteine rich	p.L629 D631>H	Thyroid medullary carcinoma
Cysteine rich	p.C630F	MEN2A/thyroid medullary carcinoma
Cysteine rich	p.C630R	Thyroid medullary carcinoma
Cysteine rich	p.C630Y	Thyroid medullary carcinoma
Cysteine rich	p.D631G	Thyroid medullary carcinoma
Cysteine rich	p.D631 C634>HELC	MEN2A
Cysteine rich	p.D631 L633>E	Thyroid medullary carcinoma
Cysteine rich	p.E632 A640>VRP	Thyroid medullary carcinoma
Cysteine rich	p.E632 C634>L	Thyroid medullary carcinoma
Cysteine rich	p.E632 L633>V	Thyroid medullary carcinoma
Cysteine rich	p.E632 L633del	Adrenal gland pheochromocytoma Thyroid medullary carcinoma
Cysteine rich	p.E632 T636>SS	Thyroid medullary carcinoma
Cysteine rich	p.C634A	Thyroid medullary carcinoma
Cysteine rich	p.C634F	MEN2A/thyroid medullary carcinoma
Cysteine rich	p.C634G	MEN2A/thyroid medullary carcinoma
Cysteine rich	p.C634S	MEN2A/thyroid medullary carcinoma
Cysteine rich	p.C634T	Thyroid medullary carcinoma
Cysteine rich	p.C634Y	Adrenal gland pheochromocytoma Thyroid medullary carcinoma
Cysteine rich	p.C634W	Thyroid medullary carcinoma, MEN2A
Cysteine rich	p.C634R	Adrenal gland pheochromocytoma Thyroid medullary carcinoma
	p.C634 T636>CRT	MEN2A
	pC634R A640G	MEN2A
	pC634S A641S	MEN2A
	pC639S A641R	Thyroid medullary carcinoma
	p.A664D	Lung SCC
Kinase	p.G748C	Thyroid medullary carcinoma
Kinase	p.P766S	Thyroid medullary carcinoma
Kinase	p.E768D	Thyroid medullary carcinoma
Kinase	p.V778V	Thyroid medullary carcinoma
Kinase	p.V778I V804M	Thyroid medullary carcinoma

Kinase	p.L790F	MEN2A/thyroid medullary carcinoma
Kinase	p.Y791F	MEN2A/thyroid medullary carcinoma
Kinase	p.V804L	Thyroid medullary carcinoma
Kinase	p.V804M	Thyroid medullary carcinoma
Kinase	p.V804M Y806C	De novo MEN2B
Kinase	p.E805K	Thyroid medullary carcinoma
Kinase	p.M848T	Thyroid medullary carcinoma
Kinase	p.A876V	Thyroid medullary carcinoma
Kinase	p.R878*	Lung adenocarcinoma
Kinase	p.A883P	Thyroid medullary carcinoma
Kinase	p.A883S	Thyroid medullary carcinoma
Kinase	p.A883F	Thyroid medullary carcinoma
Kinase	p.A883T	Thyroid medullary carcinoma
Kinase	p.E884K	Thyroid medullary carcinoma
Kinase	p.R886W	AS-thyroid medullary carcinoma
Kinase	p.S891A	Thyroid medullary carcinoma
Kinase	p.D898 E901del	Thyroid medullary carcinoma
Kinase	p.E901K	Thyroid medullary carcinoma
Kinase	p.S904F	Thyroid medullary carcinoma
Kinase	p.R908K	Thyroid medullary carcinoma
Kinase	p.G911D	Thyroid medullary carcinoma
Kinase	p.M918T	Adrenal gland pheochromocytoma
		Thyroid medullary carcinoma
Kinase	p.A919V	Thyroid medullary carcinoma
Kinase	p.E921K	Thyroid medullary carcinoma
Kinase	p.S922P	Thyroid medullary carcinoma
Kinase	p.L923V	Lung adenocarcinoma
Kinase	p.D925H	Adrenal gland pheochromocytoma
		Thyroid medullary carcinoma
Kinase	p.T930M	Thyroid medullary carcinoma
Kinase	p.D974D	Large intestine adenocarcinoma
		Thyroid medullary carcinoma
pfam B 26892Kinase	p.F1112Y	Urinary tract bladder carcinoma
		Thyroid medullary carcinoma

## SOURCES

---

- Forbes SA, Bhamra G, Bamford S, Dawson E, Kok C, Clements J, Menzies A, Teague JW, Futreal PA, Stratton MR. The Catalog of Somatic Mutations in Cancer (COSMIC). *Curr Protocols Hum Genet*. 2008 Apr; Chapter 10: Unit 10.11.
- Arighi E, Borrello MG, Sariola H. RET tyrosine kinase signaling in development and cancer. *Cytokine Growth Factor Rev* 2005;16(4–5):441–467.
- Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, Fulton L, Fulton RS, Zhang Q, Wendl MC, Lawrence MS, Larson DE, Chen K, Dooling DJ, Sabo A, Hawes AC, Shen H, Jhangiani SN, Lewis LR, Hall O, Zhu Y, Mathew T, Ren Y, Yao J, Scherer SE, Clerc K, Metcalf GA, Ng B, Milosavljevic A, Gonzalez-Garay ML, Osborne JR, Meyer R, Shi X, Tang Y, Koboldt DC, Lin L, Abbott R, Miner TL, Pohl C, Fewell G, Haipek C, Schmidt H, Dunford-Shore BH, Kraja A, Crosby SD, Sawyer CS, Vickery T, Sander S, Robinson J, Winckler W, Baldwin J, Chirieac LR, Dutt A, Fennell T, Hanna M, Johnson BE, Onofrio RC, Thomas RK, Tonon G, Weir BA, Zhao X, Ziaugra L, Zody MC, Giordano T, Orringer MB, Roth JA, Spitz MR, Wistuba II, Ozenberger B, Good PJ, Chang AC, Beer DG, Watson MA, Ladanyi M, Broderick S, Yoshizawa A, Travis WD, Pao W, Province MA, Weinstock GM, Varmus HE, Gabriel SB, Lander ES, Gibbs RA, Meyerson M, Wilson RK. Somatic mutations affect key pathways in lung adenocarcinoma. *Nature* 2008;455(7216):1069–1075.
- Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, Agate L, Vivaldi A, Faviana P, Basolo F, Miccoli P, Berti P, Pacini F, Pinchera A. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. *J Clin Endocrinol Metab* 2008;93(3):682–687.
- Elisei R, Romei C, Cosci B, Agate L, Bottici V, Molinaro E, Sculli M, Miccoli P, Basolo F, Grasso L, Pacini F, Pinchera A. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. *J Clin Endocrinol Metab* 2007;92(12):4725–4729.
- Hoppner W, Ritter MM. A duplication of 12bp in the critical cysteine rich domain of the RET proto-oncogene results in a distinct phenotype of multiple endocrine neoplasia type 2A. *Hum Mol Genet* 1997;6(4):587–590.
- Kodama Y, Asai N, Kawai K, Jijiwa M, Murakumo Y, Ichihara M, Takahashi M. The RET proto-oncogene: a molecular therapeutic target in thyroid cancer. *Cancer Sci* 2005;96(3):143–148.
- Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. An integrated genomic analysis of human glioblastoma multiforme. *Science* 2008;321(5897):1807–1812.